111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肥胖症微针给药技术的进展：机制、应用及展望
Authors Wu C, Zong Z, Hua F, Wu J, Shen Y, Tian Y, Chen Y
Received 8 September 2025
Accepted for publication 2 December 2025
Published 18 December 2025 Volume 2025:20 Pages 15213—15234
DOI https://doi.org/10.2147/IJN.S566132
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Professor Jie Huang
Chengyu Wu,1,* Ziliang Zong,2,* Feiran Hua,2 Jiong Wu,3 Yan Shen,3 Yu Tian,4 Yigang Chen1,2
1Department of General Surgery, The Affiliated Wuxi No. 2 Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214002, People’s Republic of China; 2Jiangnan University Medical Center (Wuxi No.2 People’ s Hospital), Wuxi, Jiangsu Province, 214000, People’s Republic of China; 3Department of Pharmaceutics, State Key Laboratory of Nature Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China; 4School of Medicine, Shanghai University, Shanghai, 200444, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yu Tian; Yigang Chen, Email shu_yutian@shu.edu.cn; 9862023226@jiangnan.edu.cn
Abstract: Obesity is a multifactorial metabolic disorder associated with increased risks of diabetes, cardiovascular disease, and other comorbidities. Conventional pharmacological interventions are often limited by poor patient adherence, systemic side effects, and suboptimal drug bioavailability. Microneedle (MN)-based transdermal drug delivery systems have emerged as a promising alternative, offering minimally invasive, painless, and patient-friendly administration. MN platforms not only bypass gastrointestinal degradation and hepatic first-pass metabolism but also enable targeted delivery to adipose tissue, thereby reducing systemic toxicity. Recent studies have demonstrated the potential of MNs to deliver diverse therapeutic agents, including small molecules, peptides, nucleic acids, and nanoparticles, for regulating adipose tissue metabolism, modulating the inflammatory microenvironment, and promoting browning of white adipose tissue. Various MN designs, such as dissolving, hydrogel-forming, and stimuli-responsive systems, allow precise control over release kinetics, ranging from ultrarapid drug exposure to long-term sustained delivery. Despite these advantages, several key challenges hinder clinical translation, including limited drug loading capacity, interindividual variability in skin penetration, potential local skin reactions with chronic use, and the difficulty of scaling up MN fabrication to Good Manufacturing Practice (GMP) standards while maintaining reproducibility and quality. Future perspectives emphasize the integration of nanocarrier systems, artificial intelligence-driven MN design, and multifunctional wearable devices to achieve personalized and adaptive therapy. With continued technological and translational advances, MN-based delivery could enable a new approach for obesity treatment, pending robust clinical validation.
Keywords: obesity, microneedle, transdermal drug delivery, adipose tissue metabolism
1Department of General Surgery, The Affiliated Wuxi No. 2 Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214002, People’s Republic of China; 2Jiangnan University Medical Center (Wuxi No.2 People’ s Hospital), Wuxi, Jiangsu Province, 214000, People’s Republic of China; 3Department of Pharmaceutics, State Key Laboratory of Nature Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China; 4School of Medicine, Shanghai University, Shanghai, 200444, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yu Tian; Yigang Chen, Email shu_yutian@shu.edu.cn; 9862023226@jiangnan.edu.cn
Abstract: Obesity is a multifactorial metabolic disorder associated with increased risks of diabetes, cardiovascular disease, and other comorbidities. Conventional pharmacological interventions are often limited by poor patient adherence, systemic side effects, and suboptimal drug bioavailability. Microneedle (MN)-based transdermal drug delivery systems have emerged as a promising alternative, offering minimally invasive, painless, and patient-friendly administration. MN platforms not only bypass gastrointestinal degradation and hepatic first-pass metabolism but also enable targeted delivery to adipose tissue, thereby reducing systemic toxicity. Recent studies have demonstrated the potential of MNs to deliver diverse therapeutic agents, including small molecules, peptides, nucleic acids, and nanoparticles, for regulating adipose tissue metabolism, modulating the inflammatory microenvironment, and promoting browning of white adipose tissue. Various MN designs, such as dissolving, hydrogel-forming, and stimuli-responsive systems, allow precise control over release kinetics, ranging from ultrarapid drug exposure to long-term sustained delivery. Despite these advantages, several key challenges hinder clinical translation, including limited drug loading capacity, interindividual variability in skin penetration, potential local skin reactions with chronic use, and the difficulty of scaling up MN fabrication to Good Manufacturing Practice (GMP) standards while maintaining reproducibility and quality. Future perspectives emphasize the integration of nanocarrier systems, artificial intelligence-driven MN design, and multifunctional wearable devices to achieve personalized and adaptive therapy. With continued technological and translational advances, MN-based delivery could enable a new approach for obesity treatment, pending robust clinical validation.
Keywords: obesity, microneedle, transdermal drug delivery, adipose tissue metabolism